EN DE

Century Sage Scientific (1450) Fair Value & Analysis

Technology · HK · Market cap HK$1.0B

CS Century Sage Scientific 1450 · HK
PriceHK$0.8300
Fair ValueHK$1.67
Upside+101.2%
Quality64/100
Watch Century Sage Scientific for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 6.1% net margin
Low debt · generates free cash flow
6.34% dividend yield
Ranks above peers (14/14)
Moderate moat 48/100
Evidence: High Range HK$1.25 – HK$2.08 Share as image

Fair value as of: Aug 13, 2026

From 24 valuation models · updated 3 days ago

Share price +10.7% over the past month.

A solid business, screening 101% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (HK$1.25). The market is more pessimistic than our downside scenario.
  • Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$4.03 HK$0.1002 Fair Value HK$1.67 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.1002 – HK$4.03 · fair‑value band HK$1.25 – HK$2.08 · the HK$0.8300 price screens below the HK$1.67 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Century Sage Scientific (1450) currently trades at HK$0.8300, while our model-based Fair Value estimate is HK$1.67, implying the stock looks roughly 101.2% undervalued today. The Quality Score stands at 64/100 (solid quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Century Sage Scientific generated revenue of HK$1.5B at a net margin of 6.1%. Revenue grew 38.1% year over year. It earns a return on equity of 19.0%. The balance sheet holds a net cash position of HK$255M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$1.25 (bear case) to HK$2.08 (bull case); at HK$0.8300, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 27% above its 52-week low, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at -40% fair-value upside, at 101%, 1450 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$3.35 HK$5.62 HK$9.54 80
Residual Income HK$0.3800 HK$0.4900 HK$1.27 76
Rev-Margin DCF HK$1.90 HK$3.01 HK$4.65 74
All 24 models by family
DCF Models
FCF DCF HK$3.53 HK$5.29 HK$10.04 38
Owner Earnings HK$1.35 HK$2.52 HK$4.70 31
5Y Revenue Exit HK$1.90 HK$2.80 HK$4.48 39
5Y EBITDA Exit HK$2.00 HK$3.02 HK$4.84 41
5Y P/E Exit HK$2.02 HK$3.31 HK$4.88 38
10Y Revenue Exit HK$2.40 HK$3.76 HK$5.03 36
10Y EBITDA Exit HK$2.50 HK$3.94 HK$6.31 37
10Y P/E Exit HK$2.51 HK$3.96 HK$6.26 35
Earnings-Based
Graham-Dodd HK$0.4400 HK$3.09 HK$4.34 54
Lynch FV HK$0.9400 HK$1.34 HK$1.74 50
PEG = 1.0 HK$0.9400 HK$1.34 HK$1.74 46
EPV HK$0.7800 HK$0.8500 HK$0.9100 59
Multiples
P/E Multiple HK$1.08 HK$1.43 HK$1.79 63
P/S Multiple HK$0.8300 HK$1.11 HK$1.38 58
P/B Multiple HK$0.8300 HK$1.11 HK$1.38 55
EV/EBIT HK$1.35 HK$1.71 HK$2.08 53
EV/EBITDA HK$1.30 HK$1.65 HK$2.01 54
EV/Revenue HK$1.08 HK$1.44 HK$1.80 43
Asset-Based
NCAV (Graham) HK$0.1900 HK$0.2600 HK$0.3800 50
Growth DCF
Growth DCF HK$3.35 HK$5.62 HK$9.54 80
Rev-Margin DCF HK$1.90 HK$3.01 HK$4.65 74
Economic Profit
Residual Income HK$0.3800 HK$0.4900 HK$1.27 76
ROIC Compounder HK$0.8600 HK$1.03 HK$1.25 72
Growth Earnings
Growth-Adj P/E HK$1.30 HK$1.85 HK$2.41 68

Widest divergence: DCF Models (HK$3.31) versus Asset-Based (HK$0.2600). Highest evidence: Growth DCF (80).

Notify me when 1450 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$1.5B
Revenue growth (YoY) +38.1%
Net margin 6.1%
Return on equity 19.0%
Free cash flow HK$351M FY2025
P/E ratio 9.3 as of Jul 2, 2026
More key figures
Operating margin 6.7%
EPS (TTM) HK$0.0400
Dividend yield 6.3%
EPS growth (YoY) -30.4%
Net cash HK$255M FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 64/100

Of which business quality 70 · Market factors (momentum, volatility) 42

Profitability 72
Margins and returns on capital today
Quality Growth 57
Are margins and returns improving?
Cashflow 95
Earnings quality: real cash, not paper profit
Fin. Strength 89
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 63
Calm price path (market factor)
Momentum 37
Price trend over the last 3–12 months (market factor)
52W Momentum 25
Distance to the 52-week high (market factor)
Net Issuance 42
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Be Friends Holding Limited, an investment holding company, provides all-media services in the People's Republic of China.

Full company description

Be Friends Holding Limited, an investment holding company, provides all-media services in the People's Republic of China. The company offers new media services, such as marketing services to the merchants for the livestream e-commerce on the e-commerce platforms; and application solutions, including design, implementation, and support services, as well as offers broadcasting equipment. It also sells self-developed equipment and related products; and provides system maintenance services comprising maintenance, training, and other supporting services. The company serves media platforms, industrial customers, and broadcasters. The company was formerly known as Century Sage Scientific Holdings Limited and changed its name to Be Friends Holding Limited in July 2023. Be Friends Holding Limited was founded in 2007 and is headquartered in Hangzhou, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Century Sage Scientific reported revenue of HK$1.5B in FY2025 versus HK$203M in FY2021, a compound +64.5%/yr. Reported net income was HK$90.2M in FY2025.

Growth Quality 95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$1.5B
Latest YoY
+18.9%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+51.7%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+57.5%
Avg. growth/yr (14Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+8.6%
Revenue +64.5%/yr
FY21 HK$203M
FY22 HK$426M
FY23 HK$1.1B
FY24 HK$1.3B
FY25 HK$1.5B
Net income
FY21 −HK$61.6M
FY22 −HK$9.2M
FY23 HK$119M
FY24 HK$81.7M
FY25 HK$90.2M
Character of growth · EPS growth decomposed (2014-2025) +0.2 % p.a.
Revenue per share +3.0 pp

of which total revenue +7.2 pp · buybacks/dilution −4.2 pp

EBIT margin −2.6 pp
Tax rate −1.4 pp
Residual (interest, one-offs) +1.3 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch 1450: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Century Sage Scientific · Fair Value
HK$1.67 +101%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Century Sage Scientific Fair Value". https://www.fairvalue-calculator.com/stock/1450

Peer Group

Software - Application · 718 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 64 · Above median
Fair Value upside +101% · Top 25%
Return on equity (TTM) 19% · Top 25%
Return on assets 9% · Top 25%
Net margin (TTM) 6% · Above median
Operating margin (TTM) 7% · Above median
Revenue growth 38% · Top 25%
Dividend yield (TTM) 6.3% · Top 25%

Valuation Multiples vs Software - Application median · lower = cheaper

P/E (TTM) 9.3× · Cheaper than 75% of peers
P/B 1.93× · Cheaper than median
P/S (TTM) 0.69× · Cheaper than 75% of peers
P/FCF 0.4× · Cheaper than 75% of peers
EV/EBITDA 4.8× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 2
FUTURE 100 · sector 38
PAST 76 · sector 13
HEALTH 100 · sector 98
DIVIDEND 100 · sector 34

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Software - Application stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
SAP SE SAPS C$12.46 C$16.26 +30%
Shopify Inc SHOP C$209.78 C$28.76 -86%
Uber Technologies, Inc UBER $75.36 $43.66 -42%
Salesforce, Inc CRM $193.32 $249.28 +29%
ServiceNow, Inc NOW $124.94 $43.73 -65%
Cadence Design Systems, Inc CDNS $323.13 $112.57 -65%
Beijing Kingsoft Office Software, Inc 688111 ¥254.50 ¥81.23 -68%
Tata Elxsi Limited TATAELXSI ₹3,712 ₹2,519 -32%
Douzone Bizon Co 012510 120,000 KRW 92,181 KRW -23%
KFin Technologies Limited KFINTECH ₹922.00 ₹556.85 -40%

Compare Century Sage Scientific with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Century Sage Scientific (1450) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$1.67 versus a price of HK$0.8300, about +101% (undervalued).
What is the fair value of 1450?
Our model-based fair value for Century Sage Scientific is HK$1.67 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$0.8300.
What is the quality score of 1450?
Century Sage Scientific has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Century Sage Scientific (1450)?
Century Sage Scientific reported trailing-twelve-month revenue of about HK$1.5B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 1450?
The net profit margin of Century Sage Scientific is about 6.1%, meaning it keeps roughly 6.1% of revenue as net income. Based on the latest reported figures.
Does Century Sage Scientific pay a dividend?
Century Sage Scientific currently shows a dividend yield of about 6.34% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Century Sage Scientific and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.